Oral Azitromycin Prophylaxis, 250 Mg Once Daily Three-Times a Week, in Primary Antibody Deficiencies: A Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

2018 ◽  
Author(s):  
Cinzia Milito ◽  
Federica Pulvirenti ◽  
Francesco Cinetto ◽  
Vassilios Lougaris ◽  
Annarosa Soresina ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Primary Antibody ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Primary Antibody Deficiencies

scholarly journals Double-blind placebo-controlled randomized clinical trial of verapamil for chronic rhinosinusitis with nasal polyps

2017 ◽  
Vol 140 (1) ◽  
pp. 271-273 ◽  
Author(s):  
Marcel M. Miyake ◽  
Angela Nocera ◽  
Patricia Levesque ◽  
Rong Guo ◽  
Christine A. Finn ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Toxins ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 279 ◽  
Author(s):  
Youssef Bennis ◽  
Yan Cluet ◽  
Dimitri Titeca-Beauport ◽  
Najeh El Esper ◽  
Pablo Ureña ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Serum Levels ◽  
Uremic Toxins ◽  
In Vitro Experiments ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Ckd Stage ◽  
Sevelamer Carbonate

High serum levels of gut-derived uremic toxins, especially p-cresyl sulfate (pCS), indoxyl sulfate (IS) and indole acetic acid (IAA), have been linked to adverse outcomes in patients with chronic kidney disease (CKD). Sevelamer carbonate could represent an interesting option to limit the elevation of gut-derived uremic toxins. The aim of the present study was to evaluate the adsorptive effect of sevelamer carbonate on different gut-derived protein-bound uremic toxins or their precursors in vitro, and its impact on the serum levels of pCS, IS and IAA in patients with CKD stage 3b/4. For the in vitro experiments, IAA, p-cresol (precursor of pCS) and indole (precursor of IS), each at a final concentration of 1 or 10 µg/mL, were incubated in centrifugal 30 kDa filter devices with 3 or 15 mg/mL sevelamer carbonate in phosphate-buffered saline at a pH adjusted to 6 or 8. Then, samples were centrifuged and free uremic toxins in the filtrates were analyzed. As a control experiment, the adsorption of phosphate was also evaluated. Additionally, patients with stage 3b/4 CKD (defined as an eGFR between 15 and 45 mL/min per 1.73 m2) were included in a multicenter, double-blind, placebo-controlled, randomized clinical trial. The participants received either placebo or sevelamer carbonate (4.8 g) three times a day for 12 weeks. The concentrations of the toxins and their precursors were measured using a validated high-performance liquid chromatography method with a diode array detector. In vitro, regardless of the pH and concentration tested, sevelamer carbonate did not show adsorption of indole and p-cresol. Conversely, with 10 µg/mL IAA, use of a high concentration of sevelamer carbonate (15 mg/mL) resulted in a significant toxin adsorption both at pH 8 (mean reduction: 26.3 ± 3.4%) and pH 6 (mean reduction: 38.7 ± 1.7%). In patients with CKD stage 3b/4, a 12-week course of treatment with sevelamer carbonate was not associated with significant decreases in serum pCS, IS and IAA levels (median difference to baseline levels: −0.12, 0.26 and −0.06 µg/mL in the sevelamer group vs. 1.97, 0.38 and 0.05 µg/mL in the placebo group, respectively). Finally, in vitro, sevelamer carbonate was capable of chelating a gut-derived uremic toxin IAA but not p-cresol and indole, the precursors of pCS and IS in the gut. In a well-designed clinical study of patients with stage 3b/4 CKD, a 12-week course of treatment with sevelamer carbonate was not associated with significant changes in the serum concentrations of pCS, IS and IAA.

Sign in / Sign up

Export Citation Format

Share Document